文献速递泌尿生殖与妇科肿瘤放疗

SAVE方案中危及器官的剂量学评估

Dosimetric Evaluation of Organs at Risk From SAVE Protocol.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-04-05

SAVE是一项多机构前瞻性3期随机试验,108例早期子宫内膜癌患者随机接受短程辅助阴道残端近距离放疗(11 Gy×2次至表面)或标准治疗。实验组对直肠、膀胱、乙状结肠和尿道的剂量显著低于7 Gy×3次和5~5.5 Gy×4次方案,但与6 Gy×5次方案无差异;小肠剂量在各方案间均无统计学差异。

要点

  • 实验组11 Gy×2次至表面的直肠、膀胱、乙状结肠、尿道剂量显著低于7 Gy×3次和5~5.5 Gy×4次方案。
  • 实验组与6 Gy×5次至表面方案在上述危及器官剂量上无差异。
  • 小肠剂量在各标准治疗分次方案与实验组之间均无统计学差异。

核心结论

  • 实验性短程阴道残端近距离放疗11 Gy×2次至表面提供的生物有效剂量与标准治疗疗程相当。
  • 实验性短程方案对直肠、膀胱、乙状结肠、小肠和尿道的D2cc和D0.1cc EQD23剂量降低或相当。
  • 这可能转化为相当或更低的急性和晚期不良反应发生率。

研究设计与样本

  • SAVE为前瞻性3期多机构随机试验,108例需阴道残端近距离放疗的患者随机分入实验短程组和标准治疗组。
  • 实验组方案为11 Gy×2次至表面;标准治疗组由治疗医生决定分为7 Gy×3次至5 mm、5~5.5 Gy×4次至5 mm和6 Gy×5次至表面三个亚组。
  • 在计划CT上勾画直肠、膀胱、乙状结肠、小肠和尿道,各危及器官绝对剂量转换为2 Gy等效剂量(EQD23),采用单因素方差分析及Tukey诚实显著性差异检验进行组间比较。

主要发现

  • 实验组直肠、膀胱、乙状结肠和尿道剂量显著低于7 Gy×3次和5~5.5 Gy×4次方案。
  • 实验组与6 Gy×5次方案在上述危及器官剂量上无差异。
  • 小肠剂量在各标准治疗分次方案与实验组之间均无统计学差异。
  • 所检查危及器官的最高EQD23剂量来自最常用的7 Gy×3次分次方案。
  • 中位随访时间短,为1年,期间无孤立阴道复发。

局限性

  • 中位随访时间短,为1年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this work was to evaluate dosimetric characteristics to organs at risk (OARs) from short-course adjuvant vaginal cuff brachytherapy (VCB) in early endometrial cancer compared with standard of care (SOC) in a multi-institutional prospective randomized trial. METHODS AND MATERIALS: SAVE (Short Course Adjuvant Vaginal Brachytherapy in Early Endometrial Cancer Compared to Standard of Care) is a prospective, phase 3, multisite randomized trial in which 108 patients requiring VCB were randomized to an experimental short-course arm (11 Gy × 2 fractions [fx] to surface) and SOC arm. Those randomized to the SOC arm were subdivided into treatment groups based on treating physician discretion as follows: 7 Gy × 3 fx to 5 mm, 5 to 5.5 Gy × 4 fx to 5 mm, and 6 Gy × 5 fx to surface. To evaluate doses to OARs of each SAVE cohort, the rectum, bladder, sigmoid, small bowel, and urethra were contoured on planning computed tomography, and doses to OARs were compared by treatment arm. Absolute doses for each OAR and from each fractionation scheme were converted to 2 Gy equivalent dose (EQD23). Each SOC arm was compared with the experimental arm separately using 1-way analysis of variance, followed by pairwise comparisons using Tukey's honestly significant difference test. RESULTS: The experimental arm had significantly lower doses for rectum, bladder, sigmoid, and urethra compared with the 7 Gy × 3 and 5 to 5.5 Gy × 4 fractionation schemes; however, the experimental arm did not differ from the 6 Gy × 5 fractionation scheme. For small bowel doses, none of the SOC fractionation schemes were statistically different than the experimental. The highest EQD23 doses to the examined OARs were observed to come from the most common dose fractionation scheme of 7 Gy × 3 fx. With a short median follow-up of 1 year, there have been no isolated vaginal recurrences. CONCLUSIONS: Experimental short-course VCB of 11 Gy × 2 fx to the surface provides a comparable biologically effective dose to SOC courses. Experimental short-course VCB was found to reduce or be comparable to D2cc and D0.1cc EQD23 doses to rectum, bladder, sigmoid, small bowel, and urethra critical structures. This may translate into a comparable or lower rate of acute and late adverse effects.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kunz JN, Huang YJ, Casper AC, et al. Dosimetric Evaluation of Organs at Risk From SAVE Protocol. Int J Radiat Oncol Biol Phys. 2023. PMID: 37023988. doi:10.1016/j.ijrobp.2023.03.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。